Aurora to Participate in the TD Cowen 46th Annual Health Care Conference
MWN-AI** Summary
Aurora Cannabis Inc. (NASDAQ: ACB) is set to participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, MA. The event will feature a fireside chat with Chief Financial Officer Simona King, who will discuss Aurora's position in the global medical cannabis industry, explore key trends, and highlight market opportunities. Derek Lessard, VP of Equity Research at TD Cowen, will moderate the session.
Scheduled for 11:10 AM Eastern Time, the fireside chat will delve into Aurora's international leadership and the evolving landscape of medical cannabis. Notably, the company aims to enhance its manufacturing prowess in Canada and navigate broader market forces that influence growth within the industry.
Investors and interested parties can listen to the live webcast by registering through the provided link, which will also allow access to a replay of the discussion for 90 days afterward. This presentation follows the announcement of a transaction with Bevo Agtech Inc., reinforcing Aurora's strategic vision in the medical cannabis sector.
As a prominent player in the industry, Aurora Cannabis serves versatile markets spanning Canada, Europe, Australia, and New Zealand, emphasizing a medical-first approach and high-margin opportunities. Its strong brand portfolio includes renowned names such as Aurora®, MedReleaf®, and Whistler Medical Marijuana Co.®, supported by GMP-certified manufacturing facilities in Canada and Germany.
Investors should note that the company issued forward-looking statements, acknowledging potential risks and uncertainties that could affect its operations and market position. With a commitment to scientific expertise and quality patient care, Aurora continues to expand its footprint in the global cannabis market.
MWN-AI** Analysis
Aurora Cannabis Inc. (NASDAQ: ACB) is set to participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, which provides a promising platform for investors to gauge the company's growth trajectory and strategic direction. As the CFO, Simona King, addresses the audience, key insights into Aurora’s operations, particularly its position in the evolving medical cannabis market, will be shared.
Investors should closely monitor the topics discussed, particularly Aurora's international leadership, advancements in Canadian manufacturing, and market trends shaping the cannabis landscape. With its extensive portfolio—encompassing well-known brands such as Aurora® and MedReleaf®—and a focus on high-margin opportunities, Aurora aims to navigate competitive pressures and capitalize on growth prospects in regions like Europe, Australia, and New Zealand.
Recent developments, such as the completion of the Bevo Agtech transaction, may enhance Aurora’s operational capabilities and market competitiveness. This transaction could signify a strong strategic move, bolstering product offerings and efficiency, which may ultimately improve profit margins. Investors keen on the sector should assess the implications of such acquisitions on Aurora's financial health and market positioning.
However, it’s vital for market participants to remain cognizant of broader industry challenges, including regulatory hurdles and fluctuating consumer demand. The cannabis market remains highly volatile, affected by changing legal frameworks and evolving public perceptions.
As Aurora continues to build on its reputation for quality and reliability, potential investors would be prudent to absorb insights from the conference and consider Aurora’s adaptability and innovation in this dynamic sector. Employing a long-term perspective while factoring in the risks will be essential for making informed investment decisions in Aurora Cannabis.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NASDAQ | TSX: ACB
Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities
EDMONTON, AB, Feb. 17, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.
Conference Details
DATE: Monday, March 2, 2026
TIME: 11:10am Eastern Time | 9:10am Mountain Time
WEBCAST: Click Here
The fireside chat will be hosted by Derek Lessard, VP of Equity Research at TD Cowen. The discussion will explore Aurora's international leadership, shifts reshaping the global medical cannabis landscape, advancements in Canadian manufacturing excellence, and the broader market forces influencing the industry's growth.
To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days.
Further, the Company announces that it has completed the transaction with Bevo Agtech Inc. ("Bevo"), previously announced on February 4, 2026 (the "Bevo Transaction"). Full details of the Bevo Transaction can be found in the February 4, 2026 press release located under the Company's profile at www.sedarplus.ca.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming participation at the TD Cowen 46th Annual Health Care Conference, as well as those related to the Company's global medical cannabis market leadership.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
FAQ**
What specific growth strategies is Aurora Cannabis Inc. (NASDAQ: ACB) implementing to enhance its position in the global medical cannabis market, and how do these align with the recent trends you've observed in the industry?
Can you elaborate on the advancements in Canadian manufacturing excellence that Aurora Cannabis Inc. ACB is focusing on, and how these innovations are expected to drive operational efficiencies and product quality?
Given the recent Bevo Agtech Inc. transaction, how does Aurora Cannabis Inc. ACB plan to integrate this acquisition, and what synergies do you anticipate will enhance your product offerings and market reach?
What market forces do you believe will have the most significant impact on the growth of Aurora Cannabis Inc. (NASDAQ: ACB) in the coming years, and how is the company positioning itself to navigate these challenges and opportunities?
**MWN-AI FAQ is based on asking OpenAI questions about Aurora Cannabis Inc. (NASDAQ: ACB).
NASDAQ: ACB
ACB Trading
-0.57% G/L:
$3.475 Last:
255,556 Volume:
$3.45 Open:
